Synthesis and Preclinical Evaluation of [F]AlF-NOTA-A2P-GPC3P for Imaging of GPC3.
2/5 보강
OpenAlex 토픽 ·
Prostate Cancer Treatment and Research
Mechanisms of cancer metastasis
TGF-β signaling in diseases
To develop an effective GPC3-targeted PET probe for tumor imaging, [F]AlF-NOTA-A2P-GPC3P was synthesized by introducing the hydrophilic linker A2P into the L5 peptide scaffold.
APA
Zhisheng Jie, Kadeer Tudi, et al. (2026). Synthesis and Preclinical Evaluation of [F]AlF-NOTA-A2P-GPC3P for Imaging of GPC3.. Molecular pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.6c00356
MLA
Zhisheng Jie, et al.. "Synthesis and Preclinical Evaluation of [F]AlF-NOTA-A2P-GPC3P for Imaging of GPC3.." Molecular pharmaceutics, 2026.
PMID
42037560 ↗
Abstract 한글 요약
To develop an effective GPC3-targeted PET probe for tumor imaging, [F]AlF-NOTA-A2P-GPC3P was synthesized by introducing the hydrophilic linker A2P into the L5 peptide scaffold. The probe was efficiently radiolabeled using the [F]AlF method, exhibiting high hydrophilicity (Log = -3.11 ± 0.31) and excellent in vitro and in vivo stability. Cellular uptake assays verified that the probe was significantly more highly taken up by GPC3-positive cell lines than by GPC3-low cell lines, confirming its specific binding to GPC3-positive cells. Micro-PET/CT and biodistribution studies in GPC3-positive tumor models (ASPC1, A549-GPC3) demonstrated specific uptake, significantly improved tumor-to-background ratios (especially tumor-to-lung and tumor-to-heart ratios), and reduced hepatic accumulation compared with the reported probe. Blocking studies in GPC3-positive tumors (ASPC1) confirmed its specificity. Thus, [F]AlF-NOTA-A2P-GPC3P is a promising PET imaging agent for GPC3-positive tumor detection.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Dynamic fluorine-18 fluorodeoxyglucose PET for evaluating different-sized metastatic lymph nodes in patients with non-small cell lung cancers.
- Plasma GPC3 reflects tumor GPC3 expression and predicts clinical outcomes in advanced HCC treated with atezolizumab + bevacizumab.
- The Role of Estrogen Receptor-Targeted PET with 16α-F-Fluoro-17β-Estradiol in Predicting Response to Endocrine Therapies in Metastatic Breast Cancer: A Metaanalysis.
- Value of Multitracer Imaging in Hepatocellular Carcinomas with Different Metastatic Potential.
- Evolving strategies in prostate cancer: Emerging approaches and unmet needs from the Bridging the Gaps in Prostate Cancer expert panel.
- Shifting the paradigm of PSMA delivery in prostate cancer for internal radiotherapy: An innovative ultrasound-mediated approach.